Takeda buys US drug-developer Syrxx

By Renate Krelle
Friday, 11 February, 2005

Japanese pharmaceutical giant Takeda has paid US$270 million in cash to acquire Syrxx, a private drug-development company based in San Diego.

Syrxx is a specialist in high-throughput X-ray crystallography, which it uses to design therapeutics to treat metabolic diseases, cancer, and inflammation. It has several compounds for type 2 diabetes in preclinical and early clinical trials.

Takeda is under pressure to use its cash balance of over 1 trillion yen to fill its poor drug development pipeline. It halted development of a promising diabetes drug late last year.

Related News

Does exercise really extend lifespan? It's complicated

Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd